



REWARD E. JENKINS  
JEFFREY T. WILSON  
ARLES A. TAYLOR, JR.  
DAVID P. GLOEKLER  
GREGORY A. HUNT  
JOHN A. LAMERDIN, Ph.D.  
BENTLEY J. OLIVE  
E. ERIC MILLS  
CHRISTOPHER P. PERKINS, Ph.D.\*

\*LICENSED ONLY IN CALIFORNIA

## JENKINS & WILSON, P.A.

PATENT ATTORNEYS  
SUITE 1400 UNIVERSITY TOWER  
3100 TOWER BOULEVARD  
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000  
FACSIMILE (919) 419-0383

WEBSITE  
JENKINSANDWILSON.COM

### RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS  
VENTURE II SUITE 400  
920 MAIN CAMPUS DRIVE  
RALEIGH, NORTH CAROLINA 27606

TELEPHONE (919) 424-3710  
FACSIMILE (919) 424-3711

March 13, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on 3/13/2003.

Patty T. Wilson  
Patty T. Wilson  
Date of Signature: March 13, 2003

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
MAR 18 2003  
TECH CENTER 1600/2900

Re: U.S. Patent Application Serial No. 10/029,413 for  
PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL  
NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC  
AND SCREENING METHODS USING SAME  
Our Ref. No. 421/29/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:


1. Information Disclosure Statement (1 page);
2. Form PTO-1449 (in duplicate) (2 pages);
3. Copies of cited reference(s) (8 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Commissioner for Patents  
March 13, 2003  
Page 2

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.



Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/ptw/gwc

Enclosures

Customer No. Bar Code Label:



25297

Patent Trademark Office



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on 3/13/2003.

Patty T. Wilson  
Date of Signature 3/13/2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malouf et al.

Examiner: Not Assigned

Application No.: 10/029,413

Group Art Unit: Not Assigned

Filed: December 20, 2001

Docket No.: 421/29/2

Confirmation No.: 3695

For: PURIFIED AND ISOLATED PLATELET AND CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
MAR 18 2003  
TECH CENTER 1600/2900

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Arles A. Taylor, Jr.  
Registration No. 39,395

Date: 3/13/2003

By:

Customer No. Bar Code Label:

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

421/29/2 AAT/ptw/gwc

Enclosures


Although a check is being submitted, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 03/18/2002


By:

  
Arles A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

Customer No. Barcode Label:   
421/29/2 AAT/JAL/sed 25297  
PATENT TRADEMARK OFFICE

Enclosures

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 421/29/2	Serial No. 10/029,413
 List of Documents Cited by Applicant			
		Applicant(s): Malouf et al.	
		Filing Date: December 20, 2001	Group 1646

## U.S. PATENT DOCUMENTS


Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
	1.	5.429,921	7/4/1995	Harpold et al.	435	4	<i>RECEIVED MAR 18 2003</i>
	2.	5,686,241	11/11/1997	Ellis et al.	435	56	<i>TECH CENTER 1600/2900</i>

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	3.	Hogan, et al. <i>Human dihydroxypyridine-sensitive L-type calcium channel alpha-1 subunit (CACNL1A3) mRNA</i> , Database accession no. L33798 XP002224388 (Abstract) (December 16, 1994).
	4.	Hogan et al., <i>The Structure of the Gene Encoding the Human Skeletal Muscle <math>\alpha_1</math> Subunit of the Dihydropyridine-Sensitive L-type Calcium Channel (CACNL1A3)</i> , <i>Genomics</i> 31:392-394 (1996).
	5.	Hogan et al., <i>Cloning of the human skeletal muscle alpha-1 subunit of dihydroxypyridine-sensitive L-type calcium channel</i> , <i>Genomics</i> 24, No. 3:608-609 (December 1 1994).
	6.	Chaudhari et al., <i>Mus musculus dihydropyridine sensitive skeletal muscle calcium channel mRNA</i> , Database accession no. L06234 XP002224389 (Abstract) (November 17, 1992).
	7.	Chaudhari, <i>A Single Nucleotide Deletion in the Skeletal Muscle-specific Calcium Channel Transcript of Muscular Dysgenesis (mdg) Mice</i> , <i>J. of Biological Chemistry</i> 287, No. 36:25636-25639 (1992).

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 421/29/2	Serial No. 10/029,413
List of Documents Cited by Applicant			
		Applicant(s): Malouf et al.	
		Filing Date: December 20, 2001	Group 1646
	8.	Tang et al., <i>Molecular Localization Studies of the Dihydropyridine (DHP) Binding Site in the Cardiac L-type Voltage Dependent Ca<sup>2+</sup> Channel (L-VDCC) α<sub>1</sub> Subunit Reveal Motif IV S3 to IV S6 as Essential</i> , XP000604115 (Abstract) (1993).	

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No. 421/29/2

Serial No.  
107029413

List of Documents Cited by Applicant

Applicant(s): Malouf et al.

Filing Date: December 20, 2001

Group 1646

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No
✓	A1.	WO 95 04822 A	02/16/1995	US	Salk Institute Biotech Ind Assoc Ltd	Yes

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	1.	Ihara, Yu et al., <i>Rat rCACN4A mRNA for L-type Voltage Dependent Calcium Channel Alpha 1 Subunit</i> , Database accession no. D38101 XP002238191 (Abstract) (March 29, 1995).
✓	2.	Ihara, Yu et al., <i>Voltage-dependent L-type Voltage Calcium Channel Alpha 1D Subunit (Rat)</i> , Database accession no. P27732 XP002238193 (Abstract) (October 1, 1996).
✓	3.	Seino, S. et al., <i>Human neuroendocrine/beta-cell-type calcium channel alpha-1 subunit mRNA</i> , Database accession no. M83566 XP002238192 (Abstract) (February 3, 1992).

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.